FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

19172111000001106: Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) (product)


Status: current, Not sufficiently defined by necessary conditions definition status. Date: 29-Jun 2011. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
64306101000001117 Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
64306201000001112 Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction not available true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Is a Product containing precisely nalidixic acid 60 milligram/1 milliliter conventional release oral suspension true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has active ingredient Nalidixic acid false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has manufactured dose form Conventional release oral suspension true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) VMP non-availability indicator Available false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has specific active ingredient Nalidixic acid true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has dispensed dose form Conventional release oral suspension true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has excipient Propylene glycol false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has excipient Hydroxybenzoates false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has excipient Sorbic acid false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Has excipient Polysorbate false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) VMP non-availability indicator Not available true Inferred relationship Existential restriction modifier

Inbound Relationships Type Active Source Characteristic Refinability Group
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) 150 ml Has AMP True Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start